Judith Hsia, MD
Research Professor, Medicine-Cardiology

Publications

• Kondapalli L, Hsia J, Miller M, Flaig T, Bonaca MP. Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor-Treated Patients: Reconciling Adjudicated and Coded Outcomes, JACC CardioOnc.2022;4:649–656
• Canonico ME, Hsia J, Cannon CP, Bonaca MP. Uptake of newer guideline-directed therapies in heart failure patients with diabetes or chronic kidney disease. JACC Heart Fail 2022; 10: 989-991 doi: 10.1016/j.jchf.2022.09.013
• Hsia J, Guthrie NC, Paul Lupinacci P et al. Randomized, controlled trial of a digital behavioral therapeutic application to improve glycemic control in adults with type 2 diabetes. Diab Care 2022;45:2976-2981
• Sesso HD, Manson JAE, Aragaki AK…Hsia J et al. Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. Am J Clin Nutr 2022;115:1490-1500
• Sesso HD, Rist PM, Aragaki AK ….Hsia J et al. Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. Am J Clin Nutr 2022;115:1501-10
• Canonico ME, Hsia J, Guthrie NL et al. Cognitive Behavioral Therapy Delivered Via Digital Mobile Application for the Treatment of Type 2 Diabetes: Rationale, Design and Baseline Characteristics of a Randomized, Controlled Trial. Clin Cardiol 2022; 45: 850-856. doi.org/10.1002/clc.23853
• Hess CN, Baumgartner I, Anand SS…Hsia J. Sex-Based Differences in Outcomes following Peripheral Artery Revascularization: Insights from VOYAGER PAD, JAHA 2022;11:e024655. doi: 10.1161/JAHA.121.02465
• Hess CN, Szarek M, Anand SS …Hsia J et al. Risk of Venous Thromboembolism and Effect of Rivaroxaban in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Revascularization, JAMA Network Open 2022; 5(6): e2215580. doi:10.1001/jamanetworkopen.2022.15580
• Szarek M, Hess C, Patel MR… Hsia J et al. Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic PAD. JAHA 2022;11:e025504. doi: 10.1161/JAHA.122.025504
• Berkowitz S, Bauersachs RM, Szarek M…Hsia J et al. Prevention of Arterial And Venous Thrombotic Events In Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD trial: Dual Anticoagulant/Antiplatelet Regimen Vs Antiplatelet Therapy Alone. J Thromb Haemost 2022;20:1193–1205. doi: 10.1111/jth.15673
• Hogan SE, Nehler MR, Anand S… Hsia J, Bonaca MP. Walking Impairment Following Surgical and Endovascular Revascularization: Insights from VOYAGER PAD. Vasc Med 2022; 27: 343-9. doi: 10.1177/1358863X221085606
• Hess CN, Capell WG, Bristow MR…Hsia J, Bonaca MP. Rationale and design for the study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 study. Am Heart J 2022; 246: 136-143. doi: 10.1016/j.ahj.2021.12.010
• Bonaca MP, Guthrie NL Lupinacci P…Hsia J. Randomized, Controlled Trial of Digital Nutritional Cognitive Behavioral Therapy in Patients with Type 2 Diabetes Mellitus: Primary Outcomes of the BT-001 Pivotal Trial at 180 Days. Presented AHA Scientific Sessions 2022
• King RW, Nehler MR, Manesh R. Patel MR … Hsia J et al. Risk Stratification for Amputation in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD. Circ 2022;146:A9928
• Hogan S, Patel MR, Debus ES… Hsia J et al. Unplanned Limb Revascularization with Rivaroxaban versus Placebo in Patients with Critical Limb Ischemia after Endovascular and Surgical Treatment: Insights from VOYAGER PAD. Circ 2022;146:A10889
• Khairani C, Bejjani A, Carroll B…Hsia JA et al. Diabetes is Associated With Increased Risk of Major Adverse Cardiovascular Events in Patients Covid-19: A Retrospective US Multicenter Cohort Study. Circ 2022;146:A15606
• Piazza G, Spyropoulos A, Hsia J et al. Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic events, Hospitalization and Death in Medically Ill Outpatients With COVID-19: Primary Results of the PREVENT-HD Randomized Clinical Trial. Presented AHA Scientific Sessions 2022
• Hsia J, Spyropoulos A, Piazza G et al. Rivaroxaban to Improve Clinical Outcomes in Outpatients with COVID-19: a meta-analysis of PREVENT-HD and the Bill and Melinda Gates Medical Research Institute trial. Circ 2022;146:A10258
• Canonico ME, Capell W, Anand SS…Hsia J et al. Causes of Death in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD. Circ 2022;146:A12197
• Buchanan CE, Szarek M, Eike Sebastian Debus ES … Hsia J et al. Lower May Not Be Better: Systolic Blood Pressure and Risk of Major Adverse Limb Events in Patients with Symptomatic Peripheral Artery Disease after Revascularization: Insights from VOYAGER PAD. Circ 2022;146:A10240
• Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) are underutilized in 2021-22 in patients with heart failure without diabetes. Circ 2022;146:A10477
• Hess CN, Nehler MR, Morrison JT, Buchanan C, Anderson VE, Cannon CP, Hsia J, Bonaca MP. Pragmatic Implementation Science in Peripheral Artery Disease: Design and Conduct of OPTIMIZE PAD-1, Vasc Med doi: 10.1177/1358863X221127748, p25
• Buchanan C, Hogan SE, King RW, Nehler MR, Hsia J, Bonaca MP. Exercise therapy for symptomatic peripheral artery disease following surgical and endovascular peripheral revascularization: could we do better? Vasc Med doi: 10.1177/1358863X221127748, p20
• Hsia J, Guthrie NL, Lupinacci P, Gubbi A, Denham D, Berman MA, Bonaca MP. Randomized, controlled trial of a digital therapeutic app providing nutritional cognitive behavioral therapy for the treatment of type 2 diabetes. Vasc Med doi: 10.1177/1358863X221127748, p14
• Anderson VE, Delva-Clark H, Capell W, Hogan SE, Rogers RK, Cannon C, Hsia J, Bonaca M. Effect of course length on total distance walked during monitored 6-minute walk test within a randomized clinical trial. Vasc Med doi: 10.1177/1358863X221127748, p17
• Canonico ME, Hsia J, Hess CN, Bonaca MP. Guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease (PAD). Vasc Med doi: 10.1177/1358863X221127748, p21
• Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) for heart failure are underutilized in 2021-2 in patients with chronic kidney disease, J Am Soc Nephrol 2022;33:217
• Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) are underutilized in 2021 in patients with heart failure with or without diabetes. Diabetes 2022;71(Suppl_1):868-P doi: 10.2337/db22-868-P
• Hess CN, Nehler MR, Hsia JA et al. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN Phase 2b Randomized Trial. ATVB 2022;42 (Suppl 1):A113. Winner of the AHA Paul Dudley White International Scholar Award as the highest scoring abstract at Vascular Discovery 2022
• Svet M, Hsia J, Patel MR et al. Rivaroxaban Reduces Thrombotic Hospitalizations in Patients with Peripheral Artery Disease After Revascularization in those with and without chronic kidney disease. JACC 2022; 79: 9 Suppl 1739
• Heilman A, Bauersachs R, Anand S … Hsia J et al. Benefits of rivaroxaban after lower extremity revascularization for symptomatic peripheral artery disease are consistent with and without background statin therapy. JACC 2022; 79: 9 Suppl 1747
• Szarek M, Hess C, Patel MR…Hsia J et al. Total cardiovascular and limb events with ticagrelor and clopidogrel in patients with symptomatic PAD in the EUCLID trial. JACC 2022 79:9 Suppl 1744
• Hogan SE, Nehler MR, Anand S… Hsia J, Bonaca MP. Walking Impairment Following Surgical and Endovascular Revascularization: Insights from VOYAGER PAD. JACC 2022; 79: 9 Suppl 1774
• Canonico ME, Hsia J, Cannon CP, Bonaca MP. Sex differences in guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease. Vasc Med, in press